-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 7.7%
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 7.7%
Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Rating) shares traded down 7.7% during mid-day trading on Tuesday . The company traded as low as $13.71 and last traded at $13.71. 56,476 shares changed hands during trading, a decline of 82% from the average session volume of 305,858 shares. The stock had previously closed at $14.85.
Analysts Set New Price Targets
A number of analysts recently issued reports on the stock. Bank of America began coverage on shares of Mineralys Therapeutics in a research report on Tuesday, March 7th. They set a "buy" rating and a $39.00 target price for the company. Wells Fargo & Company began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "overweight" rating and a $27.00 price target for the company. Evercore ISI began coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued an "outperform" rating for the company. Credit Suisse Group decreased their price target on Mineralys Therapeutics from $40.00 to $38.00 and set an "outperform" rating for the company in a report on Thursday, March 16th. Finally, Stifel Nicolaus initiated coverage on Mineralys Therapeutics in a report on Tuesday, March 7th. They issued a "buy" rating and a $45.00 price target for the company. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $36.20.
Get Mineralys Therapeutics alerts:Mineralys Therapeutics Price Performance
Insider Activity at Mineralys Therapeutics
In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at approximately $29,875,664. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Ra Capital Management, L.P. purchased 1,250,000 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $20,000,000.00. Following the transaction, the director now owns 1,867,229 shares in the company, valued at approximately $29,875,664. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Scott Levy purchased 6,250 shares of the company's stock in a transaction that occurred on Tuesday, February 14th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $100,000.00. Following the completion of the transaction, the chief financial officer now owns 350,811 shares in the company, valued at approximately $5,612,976. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 1,568,750 shares of company stock valued at $25,100,000.
About Mineralys Therapeutics
(Get Rating)
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Mineralys Therapeutics Inc is based in RADNOR, Pa.
Featured Articles
- Get a free copy of the StockNews.com research report on Mineralys Therapeutics (MLYS)
- Game-Changing News For Tesla Investors
- DOW New Hghs Coming Sooner Than Later
- The Tide Is Turning For Harley-Davidson
- Why did Sarepta Therapeutics Stock Plummet?
- Microsoft Is The New Safe Haven
Receive News & Ratings for Mineralys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mineralys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
周二午盘交易中,Mineralys治疗公司(纳斯达克代码:MLYS-GET Rating)的股价下跌了7.7%。该公司股价低至13.71美元,最新报13.71美元。56,476股在交易中易手,较305,858股的平均成交量下降了82%。该股此前收盘价为14.85美元。
分析师设定新的价格目标
一些分析师最近发布了关于该股的报告。美国银行于3月7日星期二在一份研究报告中开始对Mineralys治疗公司的股票进行报道。他们为该公司设定了“买入”评级和39.00美元的目标价。富国银行公司在3月7日星期二的一份报告中开始报道Mineralys治疗公司。他们对该公司的评级为“增持”,目标价为27美元。Evercore ISI在3月7日星期二的一份报告中开始报道Mineralys治疗公司。他们对该公司的评级为“跑赢大盘”。瑞士信贷集团将Mineralys Treeutics的目标价从40.00美元下调至38.00美元,并在3月16日星期四的一份报告中为该公司设定了“跑赢大盘”的评级。最后,Stifel Nicolaus在3月7日星期二的一份报告中开始了对Mineralys治疗的报道。他们对该公司的评级为“买入”,目标价为45.00美元。根据MarketBeat的数据,6位投资分析师对该股的评级为买入,该股的平均评级为“买入”,共识目标价为36.20美元。
到达Mineralys治疗公司警报:Mineralys治疗公司的价格表现
Mineralys治疗公司的内部活动
其他新闻方面,董事在2月14日(星期二)的一笔交易中购买了125万股该公司股票。收购这些股份的平均成本为每股16.00美元,总价值为20,000,000.00美元。交易完成后,董事现在拥有该公司1867,229股股份,价值约29,875,664美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过这个环节。其他新闻方面,董事在2月14日(星期二)的一笔交易中购买了125万股该公司股票。收购这些股份的平均成本为每股16.00美元,总价值为20,000,000.00美元。交易完成后,董事现在拥有该公司1867,229股股份,价值约29,875,664美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可以通过这个环节。此外,首席财务官亚当·斯科特·利维在2月14日星期二的一次交易中购买了6250股该公司的股票。这些股票是以每股16.00美元的平均成本购买的,总交易额为100,000.00美元。交易完成后,首席财务官现在拥有该公司350,811股,价值约5,612,976美元。关于这次购买的披露可以找到这里。在过去的90天里,内部人士购买了1,568,750股公司股票,价值25,100,000美元。
关于Mineralys治疗公司
(获取评级)
Mineralys治疗公司是一家临床阶段的生物制药公司,专注于开发针对由异常升高的醛固酮引起的疾病的药物。Mineralys治疗公司的总部设在宾夕法尼亚州拉德诺。
专题文章
- 免费获取StockNews.com关于Mineralys治疗的研究报告(MLYS)
- 特斯拉投资者的改变游戏规则的消息
- 陶氏化学新HHS的到来早于晚
- 潮流正在转向哈雷-戴维森
- 为什么Sarepta治疗公司的股票暴跌?
- 微软是新的避风港
接受Mineralys治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Mineralys治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧